The Marked Chart Wire · Series of events
Series of events · Pfizer
Pfizer wins FDA approval and beats third-quarter earnings
Pfazer secured a new drug approval in October and followed it with strong third-quarter results and raised guidance in November.
Updated
The flow in 3 points
- FDA approved TALZENNA for prostate cancer in October
- Revenue hit $16.58 billion, beating estimates
- Full-year revenue guidance raised to $62 to $64 billion
What happened, in order
Times are Eastern-
Where it began
FDA clears drug
The FDA approved Pfizer's TALZENNA in combination with XTANDI for specific prostate cancer patients.
Read the story -
Estimates lowered
Analysts projected earnings per share of $0.73 and total revenue of $15.88 billion ahead of the report.
Read the story -
Latest
Earnings beat
Pfizer reported revenue of $16.58 billion and adjusted earnings per share of $0.87, both above estimates.
Read the story
How they connect
Pfizer first received FDA approval for a prostate cancer treatment in late October. The company then reported third-quarter results in early November that exceeded analyst expectations and included raised full-year guidance.
The stocks in this series
Prices from Before the open · based on Mon close · Opens 9:30 AM ET. Each tile opens the stock's chart and news.
A series is a short summary of connected news, for learning. Not verified and not advice. Check the full stories before you act.